| Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology |
64 |
| CDK4/6 inhibition in breast cancer: current practice and future directions |
52 |
| 5-fluorouracil and cardiotoxicity: a review |
43 |
| HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance |
42 |
| Treatment of uveal melanoma: where are we now? |
42 |
| Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials |
40 |
| Radiation effects on antitumor immune responses: current perspectives and challenges |
40 |
| PD-L1 expression testing in non-small cell lung cancer |
35 |
| Use of cold-atmospheric plasma in oncology: a concise systematic review |
34 |
| Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies |
32 |
| Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? |
28 |
| Clinical assessment of immune-related adverse events |
25 |
| Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies |
24 |
| Radiotherapy and checkpoint inhibitors: a winning new combination? |
24 |
| Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients |
23 |
| Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives |
20 |
| Molecular targeted therapy of BRAF-mutant colorectal cancer |
19 |
| Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer |
18 |
| Immunotherapy and pancreatic cancer: unique challenges and potential opportunities |
17 |
| Clinically relevant drug interactions with multikinase inhibitors: a review |
17 |
| Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors |
17 |
| Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review |
16 |
| An update on treatment options for pancreatic adenocarcinoma |
16 |
| Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC) |
16 |
| Overexpression of long noncoding RNA LINC01419 in esophageal squamous cell carcinoma and its relation to the sensitivity to 5-fluorouracil by mediating GSTP1 methylation |
15 |
| Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers |
14 |
| Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer |
14 |
| Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors |
14 |
| Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients |
13 |
| Approved checkpoint inhibitors in bladder cancer: which drug should be used when? |
13 |
| Upregulation of LGALS1 is associated with oral cancer metastasis |
13 |
| The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer |
11 |
| D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation |
11 |
| Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study |
11 |
| Late-line treatment in metastatic gastric cancer: today and tomorrow |
11 |
| Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer |
11 |
| A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma |
11 |
| F-18-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature |
11 |
| CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease |
11 |
| Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives |
11 |
| New frontiers in the medical management of gastrointestinal stromal tumours |
10 |
| Salvage surgery for recurrent or persistent tumour after radical (chemo)radiotherapy for locally advanced non-small cell lung cancer: a systematic review |
9 |
| Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? |
9 |
| The endonuclease APE1 processes miR-92b formation, thereby regulating expression of the tumor suppressor LDLR in cervical cancer cells |
9 |
| Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer |
9 |
| Inhibitors targeting CDK4/ PARP and PI3K in breast cancer: a review |
9 |
| Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives |
9 |
| Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma |
9 |
| Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment |
8 |
| Academic oncology clinicians' understanding of biosimilars and information needed before prescribing |
8 |
